tetano
Editor, Senior Moderator
J Control Release
. 2024 Jun 4:S0168-3659(24)00350-X.
doi: 10.1016/j.jconrel.2024.06.007. Online ahead of print. Polymeric cGAMP microparticles affect the immunogenicity of a broadly active influenza mRNA lipid nanoparticle vaccine
Dylan A Hendy[SUP] 1 [/SUP], Yutian Ma[SUP] 1 [/SUP], Timothy A Dixon[SUP] 1 [/SUP], Connor T Murphy[SUP] 1 [/SUP], Erik S Pena[SUP] 2 [/SUP], Michael A Carlock[SUP] 3 [/SUP], Ted M Ross[SUP] 4 [/SUP], Eric M Bachelder[SUP] 1 [/SUP], Kristy M Ainslie[SUP] 5 [/SUP], Owen S Fenton[SUP] 6 [/SUP]
Affiliations
Influenza outbreaks are a major burden worldwide annually. While seasonal vaccines do provide protection against infection, they are limited in that they need to be updated every year to account for the constantly mutating virus. Recently, lipid nanoparticles (LNPs) encapsulating mRNA have seen major success as a vaccine platform for SARS-CoV-2. Herein, we applied LNPs to deliver an mRNA encoding a computationally optimized broadly active (COBRA) influenza immunogen. These COBRA mRNA LNPs induced a broadly active neutralizing antibody response and protection after lethal influenza challenge. To further increase the immunogenicity of the COBRA mRNA LNPs, we combined them with acetalated dextran microparticles encapsulating a STING agonist. Contrary to recent findings, the STING agonist decreased the immunogenicity of the COBRA mRNA LNPs which was likely due to a decrease in mRNA translation as shown in vitro. Overall, this work aids in future selection of adjuvants to use with mRNA LNP vaccines.
Keywords: Acetalated dextran; COBRA; Infectious disease; STING.
. 2024 Jun 4:S0168-3659(24)00350-X.
doi: 10.1016/j.jconrel.2024.06.007. Online ahead of print. Polymeric cGAMP microparticles affect the immunogenicity of a broadly active influenza mRNA lipid nanoparticle vaccine
Dylan A Hendy[SUP] 1 [/SUP], Yutian Ma[SUP] 1 [/SUP], Timothy A Dixon[SUP] 1 [/SUP], Connor T Murphy[SUP] 1 [/SUP], Erik S Pena[SUP] 2 [/SUP], Michael A Carlock[SUP] 3 [/SUP], Ted M Ross[SUP] 4 [/SUP], Eric M Bachelder[SUP] 1 [/SUP], Kristy M Ainslie[SUP] 5 [/SUP], Owen S Fenton[SUP] 6 [/SUP]
Affiliations
- PMID: 38844178
- DOI: 10.1016/j.jconrel.2024.06.007
Influenza outbreaks are a major burden worldwide annually. While seasonal vaccines do provide protection against infection, they are limited in that they need to be updated every year to account for the constantly mutating virus. Recently, lipid nanoparticles (LNPs) encapsulating mRNA have seen major success as a vaccine platform for SARS-CoV-2. Herein, we applied LNPs to deliver an mRNA encoding a computationally optimized broadly active (COBRA) influenza immunogen. These COBRA mRNA LNPs induced a broadly active neutralizing antibody response and protection after lethal influenza challenge. To further increase the immunogenicity of the COBRA mRNA LNPs, we combined them with acetalated dextran microparticles encapsulating a STING agonist. Contrary to recent findings, the STING agonist decreased the immunogenicity of the COBRA mRNA LNPs which was likely due to a decrease in mRNA translation as shown in vitro. Overall, this work aids in future selection of adjuvants to use with mRNA LNP vaccines.
Keywords: Acetalated dextran; COBRA; Infectious disease; STING.